Uroplasty announces newly-issued patent for Urgent PC Neuromodulation System

Uroplasty, Inc. (NYSE Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today the issuance of United States Patent No. 7,668,598 covering the stimulation method used in the Urgent® PC Neuromodulation System.  The Urgent PC Neuromodulation System is a nonsurgical system for treatment of urinary urgency, urinary frequency and urinary urge incontinence, symptoms often associated with overactive bladder.

"This newly-issued patent covers the delivery of current to the sacral nerve through percutaneous electrical stimulation of the tibial nerve with our unique, disposable lead set," said David Kaysen, President and CEO. "This newly-issued patent enhances our strong patent protection for Urgent PC, which two recently published studies have shown to be effective for the treatment of patients with urinary symptoms often associated with overactive bladder. We are very pleased to have this additional protection on the unique, single-use feature of the stimulation method used in our Urgent PC System."

SOURCE Uroplasty, Inc.